NYSEAMERICAN : AIM
AIM ImmunoTech Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.164 USD (Oct 30, 2026, 9:30 AM EDT) · Market cap 4.99M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.93M |
| Enterprise Value | -1.11M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 30.44M |
| Shares Outstanding | 30.44M |
| Shares Change (YoY) | +894.51% |
| Shares Change (QoQ) | +293.40% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 3.77% |
| Float | 27.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.51 |
| Forward PS | n/a |
| PB Ratio | 0.58 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.11 |
| Quick Ratio | 2.01 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.52 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -2,382.30% |
| Return on Assets (ROA) | -82.58% |
| Return on Invested Capital (ROIC) | -175.70% |
| Return on Capital Employed (ROCE) | -143.07% |
| Weighted Average Cost of Capital (WACC) | 16.96% |
| Revenue Per Employee | $4,524 |
| Profits Per Employee | -$679,524 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -92.08% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.48 |
| Relative Strength Index (RSI) | 39.97 |
| Average Volume (20 Days) | 464,009 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.08M |
| Short Previous Month | 2.77M |
| Short % of Shares Out | 3.55% |
| Short % of Float | 3.92% |
| Short Ratio (days to cover) | 0.81 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 95,000 |
| Gross Profit | -22,000 |
| Operating Income | -11.14M |
| Pretax Income | -14.27M |
| Net Income | -14.27M |
| EBITDA | -10.73M |
| EBIT | -11.14M |
| Loss Per Share | -$2.14 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.96M |
| Total Debt | 3.92M |
| Net Cash | 6.04M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 7.74M |
| Book Value Per Share | 0.27 |
| Working Capital | 5.49M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -14.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 404,000 |
| Net Borrowing | 1.02M |
| Free Cash Flow | -14.37M |
| FCF Per Share | -$0.47 |
Margins
| Measure | Value |
|---|
| Gross Margin | -23.16% |
| Operating Margin | -11,724.21% |
| Pretax Margin | -15,021.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -894.51% |
| Shareholder Yield | n/a |
| Earnings Yield | -1,322.88% |
| FCF Yield | -305.61% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.25 |
| Price Target Difference | 2,524.96% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -50.9 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |